{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:53Z","timestamp":1792517993419,"version":"4.5.0"},"reference-count":195,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003397","name":"Huazhong University of Science and Technology","doi-asserted-by":"publisher","award":["2023BR038"],"award-info":[{"award-number":["2023BR038"]}],"id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273310"],"award-info":[{"award-number":["82273310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20451"],"award-info":[{"award-number":["U23A20451"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2022CFA016"],"award-info":[{"award-number":["2022CFA016"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2025.101989","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:04:46Z","timestamp":1766160286000},"page":"101989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of FGF19\u2013FGFR4 signaling pathway in liver health and disease: Guardian or destroyer"],"prefix":"10.1016","volume":"13","author":[{"given":"Zhangfan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers13061360","article-title":"FGF\/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1210\/er.2018-00134","article-title":"Fibroblast growth factor 15\/19: from basic functions to therapeutic perspectives","volume":"39","author":"Somm","year":"2018","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib4","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","article-title":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","volume":"75","author":"Gadaleta","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0167-4781(98)00255-3","article-title":"Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain","volume":"1444","author":"Nishimura","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.gendis.2025.101989_bib7","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","article-title":"Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members","volume":"27","author":"Goetz","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.gendis.2025.101989_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4614-0887-1_2","article-title":"Klotho and \u03b2Klotho","volume":"728","author":"Kuro-o","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"37","key":"10.1016\/j.gendis.2025.101989_bib9","doi-asserted-by":"crossref","first-page":"27277","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require Klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-7075-9-94","article-title":"Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress","volume":"9","author":"Yang","year":"2012","journal-title":"Nutr Metab"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033603","article-title":"Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism","volume":"7","author":"Ge","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/\u03b2Klotho complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","article-title":"FGF19, FGF21, and an FGFR1\/\u03b2-klotho-activating antibody act on the nervous system to regulate body weight and glycemia","volume":"26","author":"Lan","year":"2017","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/j.1460-2075.1991.tb07654.x","article-title":"FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern","volume":"10","author":"Partanen","year":"1991","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.str.2011.10.022","article-title":"The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition","volume":"20","author":"Kalinina","year":"2012","journal-title":"Structure"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1101\/gad.277137.115","article-title":"Genetic insights into the mechanisms of Fgf signaling","volume":"30","author":"Brewer","year":"2016","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.22789","article-title":"Bile acids: trying to understand their chemistry and biology with the hope of helping patients","volume":"49","author":"Hofmann","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/1566524014666140724095112","article-title":"Hepatocyte FRS2\u03b1 is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity","volume":"14","author":"Wang","year":"2014","journal-title":"Curr Mol Med"},{"issue":"8","key":"10.1016\/j.gendis.2025.101989_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gad.1773909","article-title":"Bile acid signaling pathways increase stability of small heterodimer partner (SHP) by inhibiting ubiquitin-proteasomal degradation","volume":"23","author":"Miao","year":"2009","journal-title":"Genes Dev"},{"issue":"32","key":"10.1016\/j.gendis.2025.101989_bib21","doi-asserted-by":"crossref","first-page":"23252","DOI":"10.1074\/jbc.M113.452037","article-title":"Bile acid signal-induced phosphorylation of small heterodimer partner by protein kinase C\u03b6 is critical for epigenomic regulation of liver metabolic genes","volume":"288","author":"Seok","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib22","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41467-018-04697-5","article-title":"Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis","volume":"9","author":"Byun","year":"2018","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.gendis.2025.101989_bib23","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.1074\/jbc.M808747200","article-title":"FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action","volume":"284","author":"Shin","year":"2009","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.gendis.2025.101989_bib24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.gendis.2025.101989_bib25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm1501","article-title":"Identification of a hormonal basis for gallbladder filling","volume":"12","author":"Choi","year":"2006","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.gendis.2025.101989_bib26","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.gendis.2025.101989_bib27","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho","volume":"115","author":"Ito","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib28","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/hep.22204","article-title":"Coordinate regulation of gallbladder motor function in the gut-liver axis","volume":"47","author":"Portincasa","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib29","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"issue":"6024","key":"10.1016\/j.gendis.2025.101989_bib30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib32","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Alvarez-Sola","year":"2017","journal-title":"Gut"},{"issue":"32","key":"10.1016\/j.gendis.2025.101989_bib33","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1073\/pnas.1009427107","article-title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib34","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15252\/embj.201695500","article-title":"A postprandial FGF19-SHP-LSD1 regulatory axis mediates epigenetic repression of hepatic autophagy","volume":"36","author":"Byun","year":"2017","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib35","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-020-19803-9","article-title":"Intestinal FGF15\/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.gendis.2025.101989_bib36","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":"Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man","volume":"260","author":"Lund\u00e5sen","year":"2006","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/joim.12811","article-title":"Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism","volume":"284","author":"Al-Khaifi","year":"2018","journal-title":"J Intern Med"},{"issue":"22","key":"10.1016\/j.gendis.2025.101989_bib39","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402102R","article-title":"Liver-gut axis signaling regulates circadian energy metabolism in shift workers","volume":"38","author":"Yang","year":"2024","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2025.101989_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsbmb.2012.04.008","article-title":"Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19","volume":"132","author":"Miyata","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bbrc.2013.11.126","article-title":"SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells","volume":"443","author":"Miyata","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"31","key":"10.1016\/j.gendis.2025.101989_bib43","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.3748\/wjg.v13.i31.4230","article-title":"Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR","volume":"13","author":"Wistuba","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1194\/jlr.M012781","article-title":"A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB\/NJ mice","volume":"52","author":"Henkel","year":"2011","journal-title":"J Lipid Res"},{"issue":"19","key":"10.1016\/j.gendis.2025.101989_bib46","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1074\/jbc.M110.116004","article-title":"Regulation of bile acid synthesis by fat-soluble vitamins A and D","volume":"285","author":"Schmidt","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cytogfr.2015.07.016","article-title":"Mechanisms of enterohepatic fibroblast growth factor 15\/19 signaling in health and disease","volume":"26","author":"Jahn","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib48","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmet.2013.04.007","article-title":"Diet1 functions in the FGF15\/19 enterohepatic signaling axis to modulate bile acid and lipid levels","volume":"17","author":"Vergnes","year":"2013","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000371649","article-title":"Diet1 is a regulator of fibroblast growth factor 15\/19-dependent bile acid synthesis","volume":"33","author":"Reue","year":"2015","journal-title":"Dig Dis"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1194\/jlr.M078279","article-title":"Diet1, bile acid diarrhea, and FGF15\/19: mouse model and human genetic variants","volume":"59","author":"Lee","year":"2018","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1042\/BJ20121393","article-title":"FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress","volume":"450","author":"Shimizu","year":"2013","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib52","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2337\/db21-0574","article-title":"Bromodomain inhibition reveals FGF15\/19 as a target of epigenetic regulation and metabolic control","volume":"71","author":"Kozuka","year":"2022","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.24702","article-title":"The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract","volume":"55","author":"Zweers","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2025.101989_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105265","article-title":"Alterations in bile acid kinetics after bariatric surgery in patients with obesity with or without type 2 diabetes","volume":"106","author":"Wahlstr\u00f6m","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gendis.2025.101989_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2024.175312","article-title":"Perfluorooctanoic acid (PFOA) and its alternative perfluorobutanoic acid (PFBA) alter hepatic bile acid profiles via different pathways","volume":"950","author":"Wang","year":"2024","journal-title":"Sci Total Environ"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib57","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13531","article-title":"Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD","volume":"38","author":"Nobili","year":"2018","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib60","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","article-title":"Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia","volume":"11","author":"Xu","year":"2023","journal-title":"Microbiome"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib61","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2019.10.011","article-title":"\u03b2-Klotho gene variation is associated with liver damage in children with NAFLD","volume":"72","author":"Dongiovanni","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2025.101989_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2264737","article-title":"Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota\/FXR\/FGF15 signaling pathway","volume":"2021","author":"Luo","year":"2021","journal-title":"J Immunol Res"},{"issue":"19","key":"10.1016\/j.gendis.2025.101989_bib64","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1111\/bph.16431","article-title":"Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15\/19","volume":"181","author":"Bai","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41522-023-00399-z","article-title":"Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism","volume":"9","author":"Liu","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.gendis.2025.101989_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102582","article-title":"Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice","volume":"59","author":"Zhuge","year":"2023","journal-title":"Redox Biol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101989_bib67","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: regenerate 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9972","key":"10.1016\/j.gendis.2025.101989_bib68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000005","article-title":"Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals","volume":"7","author":"Ng","year":"2023","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib70","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Al-Dury","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.gendis.2025.101989_bib72","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.gendis.2025.101989_bib73","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.gendis.2025.101989_bib74","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and optimization of non-bile acid FXR agonists as preclinical candidates for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Li","year":"2020","journal-title":"J Med Chem"},{"issue":"10126","key":"10.1016\/j.gendis.2025.101989_bib75","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib77","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib78","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib79","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.31523","article-title":"The commensal microbe Veillonella as a marker for response to an FGF19 analog in NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib81","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s44321-023-00021-x","article-title":"FGF19 and its analog aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis","volume":"16","author":"Ursic-Bedoya","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib83","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.7150\/ijbs.58776","article-title":"Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice","volume":"17","author":"Yu","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib84","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002203R","article-title":"Monomeric\/dimeric forms of Fgf15\/FGF19 show differential activity in hepatocyte proliferation and metabolic function","volume":"35","author":"Williams","year":"2021","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib85","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.gendis.2025.101989_bib87","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1096\/fj.13-231860","article-title":"Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption","volume":"27","author":"Xie","year":"2013","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib88","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/hep4.1322","article-title":"Serum metabolomic profiling identifies key metabolic signatures associated with pathogenesis of alcoholic liver disease in humans","volume":"3","author":"Yang","year":"2019","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib89","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","article-title":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis","volume":"69","author":"Brandl","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib90","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib91","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.32608","article-title":"Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation","volume":"77","author":"Jiang","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcmgh.2024.02.015","article-title":"Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease","volume":"18","author":"Ferrell","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib93","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib94","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","article-title":"Cholestatic liver disease: current treatment strategies and new therapeutic agents","volume":"81","author":"Hasegawa","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib95","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2390176","article-title":"Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion","volume":"16","author":"Wu","year":"2024","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib96","article-title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.gendis.2025.101989_bib97","article-title":"Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib98","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","article-title":"High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis","volume":"49","author":"Schaap","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib99","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/hep.32028","article-title":"Mast cells regulate ductular reaction and intestinal inflammation in cholestasis through farnesoid X receptor signaling","volume":"74","author":"Meadows","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2025.101989_bib100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tgh-20-266","article-title":"Primary sclerosing cholangitis","volume":"6","author":"Rabiee","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib101","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1096\/fba.2018-00046","article-title":"Bile acid receptor agonists in primary biliary cholangitis: regulation of the cholangiocyte secretome and downstream T cell differentiation","volume":"1","author":"Etherington","year":"2019","journal-title":"FASEB Bioadv"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib102","article-title":"Protective potential of the gallbladder in primary sclerosing cholangitis","volume":"5","author":"Cazzagon","year":"2023","journal-title":"JHEP Rep"},{"issue":"11","key":"10.1016\/j.gendis.2025.101989_bib103","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib104","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcmgh.2023.08.003","article-title":"GLP-2 improves hepatic inflammation and fibrosis in Mdr2\u2013\/\u2013 mice via activation of NR4a1\/Nur77 in hepatic stellate cells and intestinal FXR signaling","volume":"16","author":"Fuchs","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12929","article-title":"Melatonin improves cholestatic liver disease via the gut-liver axis","volume":"76","author":"Liu","year":"2024","journal-title":"J Pineal Res"},{"issue":"11","key":"10.1016\/j.gendis.2025.101989_bib106","article-title":"Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis","volume":"4","author":"Braadland","year":"2022","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib107","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/ajcn\/nqz036","article-title":"Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for end-stage intestinal failure (MESIF risk score)","volume":"109","author":"Koelfat","year":"2019","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s12276-018-0181-3","article-title":"Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling","volume":"50","author":"Xiao","year":"2018","journal-title":"Exp Mol Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib109","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2015.01.004","article-title":"Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure","volume":"62","author":"Mutanen","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib110","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/hep.32017","article-title":"Chyme reinfusion restores the regulatory bile salt-FGF19 axis in patients with intestinal failure","volume":"74","author":"Koelfat","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib111","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.32101","article-title":"Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice","volume":"75","author":"El Kasmi","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib112","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib113","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib114","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ijc.29287","article-title":"Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development","volume":"136","author":"Uriarte","year":"2015","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib115","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib116","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib117","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000488541","article-title":"Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study","volume":"8","author":"Kang","year":"2019","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib118","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.gendis.2025.101989_bib119","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/s12276-020-00524-4","article-title":"FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma","volume":"52","author":"Huynh","year":"2020","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","article-title":"Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification","volume":"67","author":"Calderaro","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib121","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1148\/radiol.2021203614","article-title":"Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular carcinoma","volume":"300","author":"Feng","year":"2021","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib122","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2020.08.013","article-title":"Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications","volume":"74","author":"Rhee","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib123","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1148\/radiol.2020192230","article-title":"Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma","volume":"295","author":"Mul\u00e9","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib125","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.7150\/thno.57659","article-title":"Homeobox B5 promotes metastasis and poor prognosis in hepatocellular carcinoma, via FGFR4 and CXCL1 upregulation","volume":"11","author":"He","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib126","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/hep.30951","article-title":"Fibroblast growth factor 19-mediated up-regulation of SYR-related high-mobility group box 18 promotes hepatocellular carcinoma metastasis by transactivating fibroblast growth factor receptor 4 and fms-related tyrosine kinase 4","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib127","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2006.02.018","article-title":"The VEGF-C\/Flt-4 axis promotes invasion and metastasis of cancer cells","volume":"9","author":"Su","year":"2006","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.gendis.2025.101989_bib128","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1158\/0008-5472.CAN-17-2039","article-title":"FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3\u03b2-Nrf2 signaling","volume":"77","author":"Teng","year":"2017","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2025.101989_bib129","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.7150\/thno.56369","article-title":"FGF19\/SOCE\/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.gendis.2025.101989_bib130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2020.11.032","article-title":"Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19\/JAK2\/STAT3 signaling","volume":"499","author":"Wu","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2025.101989_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib132","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12967-021-02807-4","article-title":"Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma","volume":"19","author":"Shin","year":"2021","journal-title":"J Transl Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib133","doi-asserted-by":"crossref","first-page":"13575","DOI":"10.18632\/oncotarget.6185","article-title":"FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3\u03b2\/\u03b2- catenin signaling cascade via FGFR4 activation","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib134","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13046-018-0781-8","article-title":"Up-regulation of FGF15\/19 signaling promotes hepatocellular carcinoma in the background of fatty liver","volume":"37","author":"Cui","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib136","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1021\/acs.jmedchem.3c02198","article-title":"FGF19-based mini probe targeting FGFR4 for diagnosis and surgical navigation of hepatocellular carcinoma","volume":"67","author":"Cai","year":"2024","journal-title":"J Med Chem"},{"issue":"40","key":"10.1016\/j.gendis.2025.101989_bib137","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208844119","article-title":"FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma","volume":"119","author":"Tao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib138","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s42004-022-00657-9","article-title":"Structure-based design of a dual-warhead covalent inhibitor of FGFR4","volume":"5","author":"Chen","year":"2022","journal-title":"Commun Chem"},{"issue":"24","key":"10.1016\/j.gendis.2025.101989_bib139","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib141","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib142","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.gendis.2025.101989_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108469","article-title":"Optimization of aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4","volume":"160","author":"Guo","year":"2025","journal-title":"Bioorg Chem"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib144","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","article-title":"FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer","volume":"18","author":"Weiss","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"10.1016\/j.gendis.2025.101989_bib145","doi-asserted-by":"crossref","first-page":"14809","DOI":"10.1021\/acs.jmedchem.2c01319","article-title":"Design, synthesis, and biological evaluation of 5-formyl-pyrrolo [3,2-b] pyridine-3-carboxamides as new selective, potent, and reversible-covalent FGFR4 inhibitors","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib146","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/acs.jmedchem.3c01810","article-title":"Discovery of 6-formylpyridyl urea derivatives as potent reversible-covalent fibroblast growth factor receptor 4 inhibitors with improved anti-hepatocellular carcinoma activity","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib147","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/acs.jmedchem.2c00096","article-title":"Design, synthesis, and biological evaluation of aminoindazole derivatives as highly selective covalent inhibitors of wild-type and gatekeeper mutant FGFR4","volume":"65","author":"Shao","year":"2022","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.gendis.2025.101989_bib148","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib149","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib150","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s12072-021-10212-8","article-title":"Targeted inhibition of FGF19\/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma","volume":"15","author":"Tai","year":"2021","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib151","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","article-title":"FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib","volume":"36","author":"Gao","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib152","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13402-017-0354-4","article-title":"Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report","volume":"41","author":"Gao","year":"2018","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib153","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1038\/s41598-021-84117-9","article-title":"The impact of FGF19\/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma","volume":"11","author":"Kanzaki","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib154","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41419-020-2413-4","article-title":"miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR","volume":"11","author":"Ji","year":"2020","journal-title":"Cell Death Dis"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2025.101989_bib155","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2017.35.15_suppl.4001","article-title":"Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)","volume":"35","author":"Cheng","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib156","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki","year":"2018","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib157","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/cas.15378","article-title":"Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma","volume":"113","author":"Iseda","year":"2022","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib158","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib159","first-page":"2733","article-title":"Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma","volume":"12","author":"Zhao","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib160","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-20-3382","article-title":"ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma","volume":"27","author":"Myojin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.gendis.2025.101989_bib161","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-20-4219","article-title":"Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study","volume":"27","author":"Finn","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib162","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/jgh3.12339","article-title":"Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma","volume":"4","author":"Shigesawa","year":"2020","journal-title":"JGH Open"},{"issue":"7518","key":"10.1016\/j.gendis.2025.101989_bib163","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature13540","article-title":"Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer","volume":"513","author":"Suh","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib164","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31568","article-title":"Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice","volume":"73","author":"Lin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2025.101989_bib165","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3389\/fphar.2019.01515","article-title":"Paracrine fibroblast growth factor 1 functions as potent therapeutic agent for intrahepatic cholestasis by downregulating synthesis of bile acid","volume":"10","author":"Lin","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib166","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/HEP.0000000000001282","article-title":"Repression of the ERR\u03b3-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib167","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib168","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.32404","article-title":"FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase\u2013caspase 6 signal axis","volume":"76","author":"Song","year":"2022","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib169","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.apsb.2023.12.012","article-title":"FGF4 protects the liver from immune-mediated injury by activating CaMKK\u03b2-PINK1 signal pathway to inhibit hepatocellular apoptosis","volume":"14","author":"Huang","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"10.1016\/j.gendis.2025.101989_bib170","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/hep.25956","article-title":"FGF3\/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma","volume":"57","author":"Arao","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib171","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib172","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jhep.2025.02.003","article-title":"Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway","volume":"83","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166870","article-title":"Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway","volume":"1870","author":"Zhou","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib174","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1038\/s41467-024-52379-2","article-title":"FGF21 modulates immunometabolic homeostasis via the ALOX15\/15-HETE axis in early liver graft injury","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41467-024-44866-3","article-title":"Short-term hypercaloric carbohydrate loading increases surgical stress resilience by inducing FGF21","volume":"15","author":"Agius","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib176","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.gendis.2025.101989_bib177","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2023.02.005","article-title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system","volume":"35","author":"Choi","year":"2023","journal-title":"Cell Metab"},{"issue":"10504","key":"10.1016\/j.gendis.2025.101989_bib178","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib179","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101989_bib180","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib181","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.gendis.2025.101989_bib182","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"10.1016\/j.gendis.2025.101989_bib183","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib184","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2025.101989_bib185","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/ncomms7980","article-title":"FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic\u2013pituitary\u2013adrenal axis","volume":"6","author":"Perry","year":"2015","journal-title":"Nat Commun"},{"issue":"10215","key":"10.1016\/j.gendis.2025.101989_bib186","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2025.101989_bib187","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.101989_bib188","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101989_bib189","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"issue":"46","key":"10.1016\/j.gendis.2025.101989_bib190","doi-asserted-by":"crossref","first-page":"29025","DOI":"10.1073\/pnas.2010984117","article-title":"Curtailing FGF19\u2019s mitogenicity by suppressing its receptor dimerization ability","volume":"117","author":"Niu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib191","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.celrep.2017.06.063","article-title":"Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor dimer stability","volume":"20","author":"Huang","year":"2017","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.gendis.2025.101989_bib192","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1665-2681(19)30766-5","article-title":"Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19","volume":"14","author":"Barrera","year":"2015","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101989_bib193","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gendis.2025.101989_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120572","article-title":"Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis","volume":"578","author":"Lu","year":"2026","journal-title":"Clin Chim Acta"},{"issue":"24","key":"10.1016\/j.gendis.2025.101989_bib195","article-title":"FGF19-induced inflammatory CAF promoted neutrophil extracellular trap formation in the liver metastasis of colorectal cancer","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"10.1016\/j.gendis.2025.101989_bib196","article-title":"FGF19-activated hepatic stellate cells release ANGPTL4 that promotes colorectal cancer liver metastasis","volume":"12","author":"Fan","year":"2025","journal-title":"Adv Sci (Weinh)"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:40:47Z","timestamp":1790012447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225004787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":195,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2352304225004787"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101989","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of FGF19\u2013FGFR4 signaling pathway in liver health and disease: Guardian or destroyer","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101989"}}